A study found there are more than 53million mugs consumed across the nation in the early hours of the day. As a result, 54 per cent of coffee drinkers can’t function properly without their ...

In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ADC from China’s SystImmune in a deal that could swell to $8.4 billion. It gives BMS ...

In-process research and development (IPRD) contributed a negative $6.39/share, driven by the Karua asset acquisition and SystImmune collaboration. The company forecasts ~$16B in operating expenses ...

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den ...

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront.

CNET’s expert staff reviews and rates dozens of new products and services each month, building on more than a quarter century of expertise.

One of the notable candidates in this field is BL-B01D1, developed by Systimmune. This EGFRxHER3 bispecific ADC employs a cleavable linker to connect a novel topoisomerase I (TOP-I) inhibitor payload.

The Advisory Committee provides strategic guidance to promote equitable and accessible healthcare. By holding organizations accountable to measurable benchmarks put in place by the Centers for ...

I am so proud of the accomplishment at SystImmune. Two new #ADCs, M11D01 and M7D01, received IND clearance from the U.S. FDA. Thankful for the hard work by the #SystImmune team!